The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer.

Background and Aim: Patients with type 2 diabetes mellitus (T2DM) have a higher risk of colorectal cancer (CRC), and those with diagnosed CRC have a poorer prognosis compared with individuals with normal glucose levels. The inhibition of sodium‐glucose cotransporter 2 (SGLT2) channels has been associated with a reduction in tumor proliferation in preclinical studies. We aimed to investigate the impact of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) on the outcome of T2DM patients with colorectal cancer. Methods: We performed a retrospective cohort study comprising adult patients with T2DM and colorectal adenocarcinoma. SGLT2i recipients were matched to non‐SGLT2i recipients in a 1:1 ratio based on age, sex, and cancer stage. The primary outcome was overall survival (OS) and progression‐free survival (PFS), and the secondary outcomes were previously reported serious adverse events associated with SGLT2i. Results: We identified 1347 patients with T2DM and colorectal adenocarcinoma, from which 92 patients in the SGLT2i cohort were matched to the non‐SGLT2i cohort. Compared to non‐SGLT2i recipients, SGLT2i recipients had a higher rate of 5‐year OS (86.2% [95% CI: 72.0–93.5] vs 62.3% [95% CI: 50.9–71.8], P = 0.013) and 5‐year PFS (76.6% [95% CI: 60.7–86.7] vs 57.0% [95% CI: 46.2–66.4], P = 0.021). In Cox proportional hazard analyses, SGLT2i were associated with a 50–70% reduction in all‐cause mortality and disease progression. SGLT2i were not associated with an increased risk of serious adverse events. Conclusion: SGLT2i were associated with a higher rate of survival in T2DM patients with colorectal cancer. [ABSTRACT FROM AUTHOR]